Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Select Advanced Solid Tumors 1Recurrence 1Pregnancy Related 1Neuroblastoma 1Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Endometrial Neoplasms 1

Interventions

Rituximab 53Cyclophosphamide 50Lenalidomide 41fludarabine 24obinutuzumab 23Prednisone 19Bendamustine Hydrochloride 19Magnetic Resonance Spectroscopy 18Vincristine 17Doxorubicin 16fludarabine phosphate 15Specimen Handling 15zanubrutinib 13Biopsy 12tazemetostat 10ibrutinib 10Whole-Body Irradiation 10pembrolizumab 9Peripheral Blood Stem Cell Transplantation 9venetoclax 8Mycophenolic Acid 7Etoposide 7axicabtagene ciloleucel 6Radiotherapy 6CT-P10 6Therapeutics 5R-CHOP protocol 5tisagenlecleucel 4tafasitamab 4polatuzumab vedotin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × Antibodies, Monoclonal × 1 year × Clear all
NCT06550141 2025-11-14

Emapalumab Prevention of CAR-T Cell Associated Toxicities

Massachusetts General Hospital

Phase 2 Recruiting
28 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡